Hutchinson China MediTech Launches Phase II Lung Cancer Drug Trial
LONDON (Alliance News) - Hutchinson China MediTech Ltd said Thursday that its majority owned research and development company has begun a Phase II clinical trial of drug fruquintinib for the treatment of non-small cell lung cancer in China. The trial is targeted at patients who have failed Read More